Pay in 4 interest-free payments of $32.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Gabelica V
inhibits UDP-glucuronosyltransferase (UGT) isoforms UGT1A6 and UGT2B7 with immunosuppressive effects
(2012) Nature Reviews Drug Discovery 11
Treatment of MCL cell lines with EPZ015666 led to inhibition of SmD3 methylation and cell death
Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542
N106 - SERCA2a SUMOylation Activator. CAS# 862974-25-2 60019 Gabelica VN106, CAS No. 862974 25 2, is a potent SERCA2a SUMOylation activator, which increases SUMOylation of SERCA2a. Decreased activity and expression of the cardiac sarcoplasmic reticulum calcium ATPase (SERCA2a), a critical pump regulating calcium cycling in cardiomyocyte, are hallmarks of heart failure. The small ubiquitin like modifier type 1 (SUMO 1) is a regulator of SERCA2a and the gene transfer of SUMO 1 in rodents and large animal models of heart